Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: A noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)

Cancer

Volumn 110, Issue 4, 2007, Pages 861-866

  Hartmann, Joerg T ^a,b   Mayer, Frank ^a   Schleicher, Jan ^c   Horger, Marius ^b   Huober, Jens ^b   Meisinger, Ines ^a   Pintoffl, Jan ^a   Käfer, Gabriele ^d   Kanz, Lothar ^a   Grünwald, Viktor ^e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c KATHARINENHOSPITAL   (Germany)

^d Hannover Medical School ^*  (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Alkylating agents; Bendamustine hydrochloride; Refractory; Second line; Soft tissue sarcoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ASPARTATE AMINOTRANSFERASE; BENDAMUSTINE; DOXORUBICIN; IFOSFAMIDE; OXAZAPHOSPHORINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DNA ALKYLATION; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GERMANY; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; LEUKOPENIA; LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELOMA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REFRACTORY CANCER; REMISSION; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; SARCOMA; TREATMENT OUTCOME;

EID: 34547871271     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22846     Document Type: Article

References (19)

1. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3-12.
2. Bauer S, Hartmann JT. Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors (GIST). Crit Rev Oncol Hematol. 2006;60:112-130.
3. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977;39:1940-1948.
4. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol. 1997;15:2378-2384.
5. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1993;31(suppl 2):S174-S179.
6. Blay JY, Van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003;39:64-69.
7. Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs. 2005;65:167-178.
8. Kopp HG, Kanz L, Hartmann JT. Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide. Anticancer Drugs. 2006;17:997-998.
9. Hartmann JT, Oechsle K, Huober J, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs. 2006;24:249-253.
10. Reichardt P, Oechsle K, Pink D, et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs. 2003;21:481-486.
11. Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res. 2003;23:1899-1901.
12. Rummel MJ, Al Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
13. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer. 2006;55:109-113.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
16. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19: 3483-3489.
17. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-2831.
18. Maki R, Hensley ML, Wathen JK, et al. A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). J Clin Oncol. 2006;24:18S. Abstract 9514.
19. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38:543-549.